RNS Number : 8303E
  Osmetech PLC
  01 October 2008
   

    THIS PRESS RELEASE IS NOT FOR DISTRIBUTION TO ANY UNITED STATES NEWSWIRE SERVICE OR OTHERWISE FOR DISTRIBUTION IN THE UNITED STATES

    PRESS RELEASE
    OSMETECH Plc
(the "Company")
    ANNOUNCEMENT
    1 October 2008

    RESULTS OF EXTRAORDINARY GENERAL MEETING
    The Company is pleased to announce that, further to its announcement on 12 September 2008, the resolution to approve the issue of up to
221,375,000 new ordinary shares and the amendments to the Company's 2003 US Equity Compensation Plan was successfully passed by shareholders
at the Company's Extraordinary General Meeting held today. As described in the announcement of 12 September, the Company is proposing to
offer American Depositary Shares ("ADSs") and new ordinary shares of 0.10p each, and to seek a listing of its ADSs on the NASDAQ Global
Market ("Offering").
    A further announcement will be made when the issue price and the actual number of ADSs and new ordinary shares proposed to be issued
pursuant to the Offering has been determined.

    Enquiries:
    Osmetech plc                                           +44 (0)207 849 6027
    James White, Chief Executive Officer
    David Sandilands, Chief Financial Officer
    Madano Partnership                                +44 (0) 207 593 4000
    Matthew Moth, Mark Way
    Canacccord Adams Limited                     +44 (0) 207 050 6500
    Robert Finlay
    L. Warren Pimm
    Lazard Capital Markets LLC
    David McMillan                                           +1 212 632 6719

    This announcement shall not constitute an offer to sell or the solicitation of an offer to buy new Ordinary Shares or ADSs or any other
security in the United States or in any such jurisdiction in which any such offer, solicitation or sale would be unlawful. New Ordinary
Shares or ADSs or other securities may not be offered or sold in the United States absent registration or an exemption from registration. 
The public offering of such securities to be made in the United States is being made by means of a prospectus that forms a part of a
registration statement filed by the Company with the US Securities and Exchange Commission and no sales of such securities shall be made nor
offers to buy be accepted until such registration statement is declared effective. A copy of the offering document may be obtained from the
Company which contains detailed information about the Company and its management, as well as the Company's most recent audited financial
statements. 

    About Osmetech plc
    (www.osmetech.com)
    Osmetech plc is a fast developing, international diagnostics business with operations in Boston and Pasadena in the US, serving the high
growth molecular diagnostic market targeting hospitals and reference laboratories. Osmetech has rights to a strong portfolio of over 200
issued and pending patents and has launched its first generation eSensor 4800 platform, an electrochemistry-based array system, together
with an FDA cleared in vitro diagnostic test for Cystic Fibrosis carrier detection. In July 2008, Osmetech received FDA clearance for its
second generation eSensor XT-8 molecular diagnostics platform and Warfarin Sensitivity Test.


This information is provided by RNS
The company news service from the London Stock Exchange
 
  END 
 
REGFFLFBVBBLFBX
Osmetech (LSE:OMH)
Historical Stock Chart
From Jun 2024 to Jul 2024 Click Here for more Osmetech Charts.
Osmetech (LSE:OMH)
Historical Stock Chart
From Jul 2023 to Jul 2024 Click Here for more Osmetech Charts.